Kedalion Therapeutics completed $5 million in Series A financing to further develop its AcuStream platform, the company announced in a press release.
Led by Lagunita Biosciences, the funding will support pilot-scale GMP manufacturing and advancement of clinical programs, the release said.
“Kedalion’s AcuStream platform has the potential to revolutionize the way that ophthalmology patients take their medications and to have great impact on comfort, convenience, compliance and adherence with their therapies,” Mark Blumenkranz, MD, MMS, executive chairman of Kedalion and chairman
Uncategorized